Biotechnology · Lexington, Massachusetts, United States
$3.64
-1.62% (-$0.06)2026-07-09
Smart-Money SignalNeutral · 51/100— Insider open-market flow is flat over 90 days
Revenue$2.6M
Net Income-$27.9M
EPS$-0.47
Market Cap$219.5M
Price Performance
Historical data including institutional events
Company Profile
A
Alfred Sandrock
CEO & Executive Director
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimerâs disease. The company also provides research program for the treatment of Huntingtonâs disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
- Founded
- 2013
- Employees
- 141
- Headquarters
- Lexington, Massachusetts, United States
- Website
- www.voyagertherapeutics.com
Peer ComparisonRevenue ($B)
▾Loading company sections...